ABSTRACT Introduction: The atypical antipsychotic (APs) drugs have become the most
widely used agents to treat a variety of psychoses because of their superiority with regard to …

The gut microbiome (GMB) plays an important role in developmental processes and has
been implicated in the etiology of psychiatric disorders. However, the relationship between …

Olanzapine is an effective antipsychotic drug but since it causes significant weight gain, it is
not well tolerated by psychosis patients. The prebiotic, B-GOS®, attenuates metabolic …

Antipsychotic drugs (APDs) are widely prescribed to control various mental disorders. As
mental disorders are chronic diseases, these drugs are often used over a life-time. However …

Abstract Background Second-generation antipsychotics (SGAs) are a mainstay therapy for
schizophrenia. SGA-treated patients present higher risk for weight gain, dyslipidemia and …

Antipsychotics frequently cause obesity and related metabolic disorders that current
psychopharmacological/endocrinological theories do not explain consistently. An …

Antipsychotic (AP) medications are associated with an increased risk of developing
metabolic side effects including weight gain, type 2 diabetes (T2D), dyslipidemia, and …

Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight
gain and metabolic alterations when administered orally to patients. Recently, we …

Aim Widely used second‐generation antipsychotics are associated with adverse metabolic
effects, contributing to increased cardiovascular mortality. To develop strategies to prevent …

Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people
worldwide. Second-generation antipsychotics (SGAs) are the cornerstone in the …